Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
NervGen Pharma Corp. is a biotechnology company focused on developing innovative treatments for nerve damage and neurodegenerative diseases, primarily through its lead product candidate, NVG-291, which targets nerve regeneration. The company operates primarily in North America and is positioned uniquely with its proprietary technology platform that leverages the role of the extracellular matrix in nerve repair.
NervGen primarily generates revenue through grants and partnerships for the development of its drug candidates, particularly NVG-291. The company has a strong competitive advantage due to its proprietary technology that enhances nerve regeneration, which is not widely available in the market.
Clinical trial results for NVG-291, particularly Phase 1 and Phase 2 data
Partnership announcements with larger pharmaceutical companies
Regulatory approvals or advancements in the drug development process
Market sentiment around neurodegenerative disease treatments
Regulatory changes affecting drug approval processes
Technological disruption from competing nerve regeneration therapies
Emergence of alternative therapies for nerve damage
Increased competition from established biotech firms with more resources
High cash burn rate with no current revenue stream
Dependency on external funding and grants
low - the demand for biotech innovations is less correlated with the economic cycle, as healthcare spending tends to remain stable.
NervGen is sensitive to interest rates as higher rates can increase the cost of capital for funding clinical trials and operations, potentially impacting its ability to raise funds.
minimal - the company currently has no debt, reducing its exposure to credit conditions.
growth - investors looking for high-risk, high-reward opportunities in the biotech sector.
high - the stock has shown significant volatility, with a 3-month return of -31.7% and a 1-year return of 72.2%.